77 results on '"Humphrey MB"'
Search Results
2. The TREM2-DAP12 signaling pathway in Nasu–Hakola disease: a molecular genetics perspective
- Author
-
Xing J, Titus AR, and Humphrey MB
- Subjects
lcsh:Biochemistry ,lcsh:Therapeutics. Pharmacology ,lcsh:RM1-950 ,lcsh:QD415-436 - Abstract
Junjie Xing,1,2 Amanda R Titus,1 Mary Beth Humphrey1–31Department of Medicine, 2Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, 3Department of Veteran's Affairs, Oklahoma City, OK, USAAbstract: Nasu–Hakola disease or polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) is a rare recessively inherited disease that is associated with early dementia and bone cysts with fractures. Here, we review the genetic causes of PLOSL with loss-of-function mutations or deletions in one of two genes, TYROBP and TREM2, encoding for two proteins DNAX-activating protein 12 (DAP12) and triggering receptor expressed on myeloid cells-2 (TREM2). TREM2 and DAP12 form an immunoreceptor signaling complex that mediates myeloid cell, including microglia and osteoclasts, development, activation, and function. Functionally, TREM2-DAP12 mediates osteoclast multi-nucleation, migration, and resorption. In microglia, TREM2-DAP12 participates in recognition and apoptosis of neuronal debris and amyloid deposits. Review of the complex immunoregulatory roles of TREM2-DAP12 in the innate immune system, where it can both promote and inhibit pro-inflammatory responses, is given. Little is known about the function of TREM2-DAP12 in normal brain homeostasis or in pathological central nervous system diseases. Based on the state of the field, genetic testing now aids in diagnosis of PLOSL, but therapeutics and interventions are still under development.Keywords: polycystic, leukoencephalopathy, Alzheimer's, lipomembranous, dementia, microglia
- Published
- 2015
3. TREM2, a DAP12-associated receptor, regulates osteoclast differentiation, migration, and resorption
- Author
-
Humphrey, Mb, Niemi, Ec, Daws, MR, and Mary C. Nakamura
4. Medication-induced fractures: Screening and treatment strategies.
- Author
-
Javed L, Khakwani A, Khan U, and Humphrey MB
- Abstract
Medication-induced osteoporosis leads to substantial fracture morbidity. With polypharmacy and the aging population in the United States, significant increases in medication-associated fractures are predicted. The most common medication to cause osteoporosis and increase fractures is glucocorticoids. Many other therapies, including loop diuretics, SGLT2 inhibitors, thiazolidinediones, proton pump inhibitors, selective serotonin reuptake inhibitors, heparin, warfarin, antiepileptics, aromatase inhibitors, anti-androgen therapies, gonadotropin-releasing hormone antagonists, and calcineurin inhibitors are associated with increased fracture risks. Here, we review the latest evidence for fracture risk for these medications and discuss fracture risk screening and management strategies., Competing Interests: Declaration of competing interest The authors whose names are listed above certify that they have no affiliation with any organization with any financial interest or non-financial interest in the subject matter or materials discussed in the manuscript., (Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
5. Protective role for kidney TREM2 high macrophages in obesity- and diabetes-induced kidney injury.
- Author
-
Subramanian A, Vernon KA, Zhou Y, Marshall JL, Alimova M, Arevalo C, Zhang F, Slyper M, Waldman J, Montesinos MS, Dionne D, Nguyen LT, Cuoco MS, Dubinsky D, Purnell J, Keller K, Sturner SH, Grinkevich E, Ghoshal A, Kotek A, Trivioli G, Richoz N, Humphrey MB, Darby IG, Miller SJ, Xu Y, Weins A, Chloe-Villani A, Chang SL, Kretzler M, Rosenblatt-Rosen O, Shaw JL, Zimmerman KA, Clatworthy MR, Regev A, and Greka A
- Subjects
- Animals, Mice, Humans, Male, Mice, Inbred C57BL, Female, Receptors, Immunologic metabolism, Receptors, Immunologic genetics, Membrane Glycoproteins metabolism, Membrane Glycoproteins genetics, Macrophages metabolism, Obesity metabolism, Obesity pathology, Obesity complications, Diabetic Nephropathies metabolism, Diabetic Nephropathies pathology, Kidney pathology, Kidney metabolism, Diet, High-Fat, Mice, Knockout
- Abstract
Diabetic kidney disease (DKD), the most common cause of kidney failure, is a frequent complication of diabetes and obesity, and yet to date, treatments to halt its progression are lacking. We analyze kidney single-cell transcriptomic profiles from DKD patients and two DKD mouse models at multiple time points along disease progression-high-fat diet (HFD)-fed mice aged to 90-100 weeks and BTBR ob/ob mice (a genetic model)-and report an expanding population of macrophages with high expression of triggering receptor expressed on myeloid cells 2 (TREM2) in HFD-fed mice. TREM2
high macrophages are enriched in obese and diabetic patients, in contrast to hypertensive patients or healthy controls in an independent validation cohort. Trem2 knockout mice on an HFD have worsening kidney filter damage and increased tubular epithelial cell injury, all signs of worsening DKD. Together, our studies suggest that strategies to enhance kidney TREM2high macrophages may provide therapeutic benefits for DKD., Competing Interests: Declaration of interests A.Greka has a financial interest in Sail Bio, which was reviewed and is managed by Brigham and Women’s Hospital, Mass General Brigham (MGB), and the Broad Institute of MIT and Harvard in accordance with their conflict of interest policies. K.A.V. is an employee and shareholder of Q32 Bio, Inc. J.L.S. is an equity holder of Magnetic Ventures. A.R. is a cofounder and equity holder of Celsius Therapeutics and equity holder of Immunitas and, until August 2020, was an SAB member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics, and Asimov. A.R. is an employee of Genentech, Inc. O.R.-R is an employee of Genentech, Inc. O.R.-R. is a coinventor on patent applications filed by the Broad Institute related to single-cell genomics., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
6. SHIP inhibition mediates select TREM2-induced microglial functions.
- Author
-
Ramakrishnan GS, Berry WL, Pacherille A, Kerr WG, Chisholm JD, Pedicone C, and Humphrey MB
- Subjects
- Animals, Humans, Alzheimer Disease metabolism, Alzheimer Disease genetics, Amyloid beta-Peptides metabolism, Apoptosis genetics, Cell Line, Lysosomes metabolism, Mitochondria metabolism, Signal Transduction, Membrane Glycoproteins metabolism, Membrane Glycoproteins genetics, Microglia metabolism, Phagocytosis genetics, Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases genetics, Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases metabolism, Receptors, Immunologic metabolism, Receptors, Immunologic genetics
- Abstract
Microglia play a pivotal role in the pathology of Alzheimer's Disease (AD), with the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) central to their neuroprotective functions. The R47H variant of TREM2 has emerged as a significant genetic risk factor for AD, leading to a loss-of-function phenotype in mouse AD models. This study elucidates the roles of TREM2 in human microglia-like HMC3 cells and the regulation of these functions by SH2-containing inositol-5'-phosphatase 1 (SHIP1). Using stable cell lines expressing wild-type TREM2, the R47H variant, and TREM2-deficient lines, we found that functional TREM2 is essential for the phagocytosis of Aβ, lysosomal capacity, and mitochondrial activity. Notably, the R47H variant displayed increased phagocytic activity towards apoptotic neurons. Introducing SHIP1, known to modulate TREM2 signaling in other cells, revealed its role as a negative regulator of these TREM2-mediated functions. Moreover, pharmacological inhibition of both SHIP1 and its isoform SHIP2 amplified Aβ phagocytosis and lysosomal capacity, independently of TREM2 or SHIP1 expression, suggesting a potential regulatory role for SHIP2 in these functions. The absence of TREM2, combined with the presence of both SHIP isoforms, suppressed mitochondrial activity. However, pan-SHIP1/2 inhibition enhanced mitochondrial function in these cells. In summary, our findings offer a deeper understanding of the relationship between TREM2 variants and SHIP1 in microglial functions, and emphasize the therapeutic potential of targeting the TREM2 and SHIP1 pathways in microglia for neurodegenerative diseases., Competing Interests: Declaration of Competing Interest WGK, CP and JDC have patents issued and pending regarding the use of SHIP paralog inhibitors in disease. The other authors declare no conflict of interest., (Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
7. HIV-Associated Rheumatic Diseases: A Narrative Review.
- Author
-
Akram B, Khan M, and Humphrey MB
- Subjects
- Humans, HIV, Antiretroviral Therapy, Highly Active, HIV Infections complications, HIV Infections drug therapy, HIV Infections epidemiology, Autoimmune Diseases diagnosis, Autoimmune Diseases epidemiology, Rheumatic Diseases drug therapy
- Abstract
Abstract: Human immunodeficiency virus (HIV) is widely prevalent among the world population. Although, historically, it has been linked to opportunistic infections in keeping with immunodeficiency and immune dysregulation, it has also been associated with a wide variety of autoimmune manifestations. With the introduction of highly active antiretroviral therapy and subsequent restoration of immunity, there have been multiple immune-mediated diseases that have resurfaced in the HIV population. Our review highlights autoimmune diseases in association with HIV and its targeted therapies in detail., Competing Interests: The authors declare no conflict of interest. There is no history of personal and professional benefit derived from the writing of this review., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
- Author
-
Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, Caplan L, Gore S, Grossman J, Hansen KE, Lane NE, Ma NS, Magrey M, McAlindon T, Robinson AB, Saha S, Womack C, Abdulhadi B, Charles JF, Cheah JTL, Chou S, Goyal I, Haseltine K, Jackson L, Mirza R, Moledina I, Punni E, Rinden T, Turgunbaev M, Wysham K, Turner AS, and Uhl S
- Subjects
- Adult, Child, Humans, United States, Glucocorticoids adverse effects, Bone Density, Rheumatology, Osteoporosis chemically induced, Osteoporosis diagnosis, Osteoporosis drug therapy
- Abstract
Objective: The objective is to update recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic conditions receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily., Methods: An updated systematic literature review was performed for clinical questions on nonpharmacologic, pharmacologic treatments, discontinuation of medications, and sequential therapy. Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the certainty of evidence. A Voting Panel achieved ≥70% consensus on the direction (for or against) and strength (strong or conditional) of recommendations., Results: For adults beginning or continuing >3 months of GC treatment, we strongly recommend as soon as possible after initiation of GCs, initial assessment of fracture risks with clinical fracture assessment, bone mineral density with vertebral fracture assessment or spinal x-ray, and Fracture Risk Assessment Tool if ≥40 years old. For adults at medium, high, or very high fracture risk, we strongly recommend pharmacologic treatment. Choice of oral or intravenous bisphosphonates, denosumab, or parathyroid hormone analogs should be made by shared decision-making. Anabolic agents are conditionally recommended as initial therapy for those with high and very high fracture risk. Recommendations are made for special populations, including children, people with organ transplants, people who may become pregnant, and people receiving very high-dose GC treatment. New recommendations for both discontinuation of osteoporosis therapy and sequential therapies are included., Conclusion: This guideline provides direction for clinicians and patients making treatment decisions for management of GIOP. These recommendations should not be used to limit or deny access to therapies., (© 2023 American College of Rheumatology. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.)
- Published
- 2023
- Full Text
- View/download PDF
9. The inhibitor of MyoD Family A (I-MFA) regulates megakaryocyte lineage commitment and terminal differentiation.
- Author
-
Houser JS, Patel M, Wright K, Onopiuk M, Tsiokas L, and Humphrey MB
- Subjects
- Mice, Animals, Cell Differentiation, Hematopoiesis, Bone Marrow Cells pathology, Cell Lineage, Megakaryocytes, Bone Marrow metabolism
- Abstract
Hematopoiesis and lineage commitment are regulated by several conserved cell-intrinsic signaling pathways, including MAPKs and β-catenin/TCF/LEF. The Inhibitor of MyoD Family A (I-MFA), a transcriptional repressor and tumor suppressor gene, interacts with these pathways and is dysregulated in chronic and acute myeloid leukemias, suggesting it may play a role in development and differentiation during hematopoiesis. To study this, immune cell populations in the bone marrow (BM) and periphery were analyzed in mice lacking Mdfi, encoding I-MFA (I-MFA-/-), and wild type (WT) controls. I-MFA-/- mice had reduced spleen and BM cellularity, with significant hyposplenism, compared to WT mice. In blood, total red blood cells and platelet counts were significantly reduced in I-MFA-/- mice, accompanied by a reduction in megakaryocyte (MK)/erythrocyte progenitor cells and an increase in myeloid progenitors in BM compared to WT mice. The K562 cell line exhibits PMA-induced MK differentiation, and shRNA knockdown of I-MFA resulted in reduced differentiation compared to control, with an increase and prolongation in phospho-JNK and phospho-ERK signaling. Overexpression of I-MFA promoted MK differentiation. These results suggest I-MFA plays a cell-intrinsic role in the response to differentiation signals, an effect that can be explored in the context of hematological cancers or other blood proliferative disorders., Competing Interests: Declaration of competing interest All authors have no competing interests to disclose related to this work., (Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
10. Cx3cr1 controls kidney resident macrophage heterogeneity.
- Author
-
Yashchenko A, Bland SJ, Song CJ, Ahmed UKB, Sharp R, Darby IG, Cordova AM, Smith ME, Lever JM, Li Z, Aloria EJ, Khan S, Maryam B, Liu S, Crowley MR, Jones KL, Zenewicz LA, George JF, Mrug M, Crossman DK, Hopp K, Stavrakis S, Humphrey MB, Ginhoux F, and Zimmerman KA
- Subjects
- Mice, Animals, Kidney metabolism, Receptors, Chemokine metabolism, Disease Models, Animal, CX3C Chemokine Receptor 1 genetics, CX3C Chemokine Receptor 1 metabolism, Macrophages metabolism, Monocytes metabolism
- Abstract
Kidney macrophages are comprised of both monocyte-derived and tissue resident populations; however, the heterogeneity of kidney macrophages and factors that regulate their heterogeneity are poorly understood. Herein, we performed single cell RNA sequencing (scRNAseq), fate mapping, and parabiosis to define the cellular heterogeneity of kidney macrophages in healthy mice. Our data indicate that healthy mouse kidneys contain four major subsets of monocytes and two major subsets of kidney resident macrophages (KRM) including a population with enriched Ccr2 expression, suggesting monocyte origin. Surprisingly, fate mapping data using the newly developed Ms4a3
Cre Rosa Stopf/f TdT model indicate that less than 50% of Ccr2+ KRM are derived from Ly6chi monocytes. Instead, we find that Ccr2 expression in KRM reflects their spatial distribution as this cell population is almost exclusively found in the kidney cortex. We also identified Cx3cr1 as a gene that governs cortex specific accumulation of Ccr2+ KRM and show that loss of Ccr2+ KRM reduces the severity of cystic kidney disease in a mouse model where cysts are mainly localized to the kidney cortex. Collectively, our data indicate that Cx3cr1 regulates KRM heterogeneity and niche-specific disease progression., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Yashchenko, Bland, Song, Ahmed, Sharp, Darby, Cordova, Smith, Lever, Li, Aloria, Khan, Maryam, Liu, Crowley, Jones, Zenewicz, George, Mrug, Crossman, Hopp, Stavrakis, Humphrey, Ginhoux and Zimmerman.)- Published
- 2023
- Full Text
- View/download PDF
11. Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: A retrospective, propensity-matched cohort study.
- Author
-
Gentry CA, Thind SK, Williams RJ 2nd, Hendrickson SC, Kurdgelashvili G, and Humphrey MB
- Subjects
- Humans, Cohort Studies, COVID-19 Drug Treatment, Hydroxychloroquine therapeutic use, Retrospective Studies, SARS-CoV-2, Arthritis, Rheumatoid complications, Arthritis, Rheumatoid drug therapy, COVID-19, Rheumatic Diseases complications, Rheumatic Diseases drug therapy
- Abstract
Background: The primary purpose of the current study was to examine whether patients with rheumatologic conditions receiving only chronic hydroxychloroquine therapy for their disease are at less risk of developing SARS-CoV-2 infection than a comparative group of patients without rheumatologic conditions., Methods: A retrospective, observational, nationwide stratified propensity analysis was conducted comparing patients only on chronic treatment with hydroxychloroquine for their rheumatologic condition to a random sample of patients without rheumatologic conditions and not receiving hydroxychloroquine, utilizing a Veterans Health Administration nationwide clinical administrative database., Results: The 1-to-1 stratified propensity analysis was undertaken using a random sample of patients without rheumatoid conditions and not receiving hydroxychloroquine (n 33,081) and patients with rheumatoid conditions receiving hydroxychloroquine as the lone medication for their condition (n 6047). A total of 5,474 patients in each group were successfully matched. The incidence of documented SARS-CoV-2 infections during the study period did not differ between patients receiving hydroxychloroquine and patients not receiving hydroxychloroquine (41/5,474 [0.749%] vs. 36/5,474 [0.658%], respectively, p = 0.57; Odds ratio [OR] 1.14, 95% confidence interval [CI] 0.73-1.79). There were no statistically-significant differences in secondary outcomes between the two groups in patients who developed active SARS-CoV-2 infection. Multivariate logistic regression to determine independent variables associated with the development of active SARS-CoV-2 infection failed to include receipt of hydroxychloroquine (OR 0.99, 95% CI 0.62-1.56)., Conclusions: Hydroxychloroquine failed to demonstrate a preventative effect against SARS-CoV-2 infection in a large group of patients with rheumatologic conditions compared to patients without rheumatologic conditions., Competing Interests: Declaration of Competing Interest CAG: None MBH: None SKT: None RJW: None SCH: None GK: None., (Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
12. Transcutaneous Vagus Nerve Stimulation Ameliorates the Phenotype of Heart Failure With Preserved Ejection Fraction Through Its Anti-Inflammatory Effects.
- Author
-
Elkholey K, Niewiadomska M, Morris L, Whyte S, Houser J, Humphrey MB, and Stavrakis S
- Subjects
- Animals, Anti-Inflammatory Agents therapeutic use, Cytokines metabolism, Fibrosis, Humans, Infant, Inflammation drug therapy, Phenotype, Rats, Rats, Inbred Dahl, Stroke Volume physiology, alpha7 Nicotinic Acetylcholine Receptor therapeutic use, Heart Failure drug therapy, Vagus Nerve Stimulation
- Abstract
Background: A systemic proinflammatory state plays a central role in the development of heart failure with preserved ejection fraction (HFpEF). Low-level transcutaneous vagus nerve stimulation (LLTS) suppresses inflammation in animals and humans, mediated by an α7nAchR (alpha7 nicotinic acetylcholine receptor)-dependent pathway. We examined the effects of LLTS on cardiac function, inflammation, and fibrosis in the presence of α7nAchR pharmacological blockade in a rat model of HFpEF., Methods: Dahl salt-sensitive rats at 7 weeks of age were treated with high-salt diet for 6 weeks to induce HFpEF, followed by 4 weeks of (1) LLTS, (2) LLTS with the α7nAchR blocker methyllycaconitine, (3) sham, and (4) olmesartan. Blood pressure, cardiac function by echocardiography, heart rate variability, and serum cytokines were measured at 13 and 17 weeks of age. Cardiac fibrosis, inflammatory cell infiltration, and gene expression were determined at 17 weeks., Results: LLTS attenuated the increase in blood pressure; improved cardiac function; decreased inflammatory cytokines, macrophage infiltration, and fibrosis; and improved survival compared with other groups. Methyllycaconitine attenuated these effects, whereas olmesartan did not improve cardiac function or fibrosis despite maintaining similar blood pressure as LLTS. Heart rate variability was similarly improved in the LLTS and LLTS plus methyllycaconitine groups but remained low in the other groups. LLTS reversed the dysregulated inflammatory signaling pathways in HFpEF hearts., Conclusions: Neuromodulation with LLTS improved cardiac function in a rat model of HFpEF through its anti-inflammatory and antifibrotic effects. These results provide the basis for further clinical trials in humans.
- Published
- 2022
- Full Text
- View/download PDF
13. Neuromodulation of Inflammation to Treat Heart Failure With Preserved Ejection Fraction: A Pilot Randomized Clinical Trial.
- Author
-
Stavrakis S, Elkholey K, Morris L, Niewiadomska M, Asad ZUA, and Humphrey MB
- Subjects
- Aged, Female, Humans, Inflammation therapy, Male, Middle Aged, Pilot Projects, Stroke Volume physiology, Tumor Necrosis Factor-alpha, Ventricular Function, Left physiology, Heart Failure diagnosis, Heart Failure therapy, Quality of Life
- Abstract
Background A systemic proinflammatory state plays a central role in the development of heart failure with preserved ejection fraction. Low-level transcutaneous vagus nerve stimulation suppresses inflammation in humans. We conducted a sham-controlled, double-blind, randomized clinical trial to examine the effect of chronic low-level transcutaneous vagus nerve stimulation on cardiac function, exercise capacity, and inflammation in patients with heart failure with preserved ejection fraction. Methods and Results Patients with heart failure with preserved ejection fraction and at least 2 additional comorbidities (obesity, diabetes, hypertension, or age ≥65 years) were randomized to either active (tragus) or sham (earlobe) low-level transcutaneous vagus nerve stimulation (20 Hz, 1 mA below discomfort threshold), for 1 hour daily for 3 months. Echocardiography, 6-minute walk test, quality of life, and serum cytokines were assessed at baseline and 3 months. Fifty-two patients (mean age 70.4±9.2 years; 70% female) were included (active, n=26; sham, n=26). Baseline characteristics were balanced between the 2 arms. Adherence to the protocol of daily stimulation was >90% in both arms ( P >0.05). While the early mitral inflow Doppler velocity to the early diastolic mitral annulus velocity ratio did not differ between groups, global longitudinal strain and tumor necrosis factor-α levels at 3 months were significantly improved in the active compared with the sham arm (-18.6%±2.5% versus -16.0%±2.4%, P =0.002; 8.9±2.8 pg/mL versus 11.3±2.9 pg/mL, P =0.007, respectively). The reduction in tumor necrosis factor-α levels correlated with global longitudinal strain improvement (r=-0.73, P =0.001). Quality of life was better in the active arm. No device-related side effects were observed. Conclusions Neuromodulation with low-level transcutaneous vagus nerve stimulation over 3 months resulted in a significant improvement in global longitudinal strain, inflammatory cytokines, and quality of life in patients with heart failure with preserved ejection fraction. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03327649.
- Published
- 2022
- Full Text
- View/download PDF
14. FBW7 couples structural integrity with functional output of primary cilia.
- Author
-
Petsouki E, Gerakopoulos V, Szeto N, Chang W, Humphrey MB, and Tsiokas L
- Subjects
- Animals, Cell Differentiation, F-Box-WD Repeat-Containing Protein 7 metabolism, Male, Mice, Microtubule-Associated Proteins metabolism, Signal Transduction, Cilia metabolism, F-Box-WD Repeat-Containing Protein 7 genetics, Microtubule-Associated Proteins genetics
- Abstract
Structural defects in primary cilia have robust effects in diverse tissues and systems. However, how disorders of ciliary length lead to functional outcomes are unknown. We examined the functional role of a ciliary length control mechanism of FBW7-mediated destruction of NDE1, in mesenchymal stem cell (MSC) differentiation. We show that FBW7 functions as a master regulator of both negative (NDE1) and positive (TALPID3) regulators of ciliogenesis, with an overall positive net effect on primary cilia formation, MSC differentiation to osteoblasts, and bone architecture. Deletion of Fbxw7 suppresses ciliation, Hedgehog activity, and differentiation, which are partially rescued in Fbxw7/Nde1-null cells. We also show that NDE1, despite suppressing ciliogenesis, promotes MSC differentiation by increasing the activity of the Hedgehog pathway by direct binding and enhancing GLI2 activity in a cilia-independent manner. We propose that FBW7 controls a protein-protein interaction network coupling ciliary structure and function, which is essential for stem cell differentiation., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
15. Sex differences in the incidence and mode of death in rats with heart failure with preserved ejection fraction.
- Author
-
Elkholey K, Morris L, Niewiadomska M, Houser J, Ramirez M, Tang M, Humphrey MB, and Stavrakis S
- Subjects
- Animals, Female, Incidence, Male, Rats, Rats, Inbred Dahl, Sex Characteristics, Stroke Volume physiology, Ventricular Function, Left physiology, Heart Failure
- Abstract
New Findings: What is the central question of this study? Prior studies failed to address the role of sex in modifying the pathophysiology and response to therapy in heart failure with preserved ejection fraction (HFpEF), potentially introducing bias into translational findings. We aimed to explore sex differences in outcomes and sought to identify the underlying mechanisms in a well-established rat model of HFpEF. What is the main finding and its importance? Male rats with HFpEF exhibited worse survival compared with females and were at a higher risk for sudden death, attributable in part to QT prolongation, autonomic dysregulation and enhanced inflammation. These data might provide the basis for the development of sex-specific interventions in HFpEF targeting these abnormalities., Abstract: Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of heart failure, and sudden death is the leading cause of mortality. We aimed to explore sex differences in outcomes in rats with HFpEF and sought to identify the underlying mechanisms. Dahl salt-sensitive rats of either sex were randomized into high-salt diet (HS diet; 8% NaCl, n = 46, 50% female) or low-salt diet (LS diet; 0.3% NaCl; n = 24, 50% female) at 7 weeks of age. After 6 and 10 weeks of LS or HS diets, the ECG, heart rate variability, cytokines and echocardiographic parameters were measured. The animals were monitored daily for development of HFpEF and survival. Over 6 weeks of HS diet, rats developed significant hypertension and signs of HFpEF. Compared with female HS diet-fed rats, males exhibited more left ventricular dilatation, a longer QT interval, and worse autonomic tone, as assessed by heart rate variability and elevated inflammatory cytokines. Ten of 23 (46%) male rats died during follow-up, compared with two of 23 (9%) female rats (P = 0.01). There were four sudden deaths in males (with ventricular tachycardia documented in one rat), whereas the females died of heart failure. In conclusion, male rats with HFpEF exhibit worse survival compared with females and are at a higher risk for sudden death, attributable in part to QT prolongation, autonomic dysregulation and enhanced inflammation. These data might provide the basis for the development of sex-specific interventions in HFpEF targeting these abnormalities., (© 2021 The Authors. Experimental Physiology © 2021 The Physiological Society.)
- Published
- 2021
- Full Text
- View/download PDF
16. Inhibition of γ-secretase in adipocytes leads to altered IL-6 secretion and adipose inflammation.
- Author
-
Sparling DP, McCullough N, Pajvani U, and Humphrey MB
- Subjects
- 3T3-L1 Cells, Adipose Tissue pathology, Amyloid Precursor Protein Secretases antagonists & inhibitors, Animals, Biomarkers, Cytokines metabolism, Inflammation Mediators metabolism, Lipopolysaccharides immunology, Macrophage Activation immunology, Macrophages immunology, Macrophages metabolism, Macrophages pathology, Mice, Panniculitis etiology, Panniculitis pathology, Protease Inhibitors pharmacology, Signal Transduction, Adipocytes metabolism, Adipose Tissue metabolism, Amyloid Precursor Protein Secretases metabolism, Interleukin-6 biosynthesis, Panniculitis metabolism
- Abstract
Adipocyte-mediated inflammatory signalling has been proposed to alter adipose physiology in obesity and Type 2 diabetes mellitus. Novel targets for alteration of inflammatory signalling are needed to improve obesity-related outcomes. The γ-secretase enzyme complex has been suggested to play a role both in adipocyte function as well as in immune regulation. We hypothesized that adipocyte-specific γ-secretase inhibition could alter the inflammatory makeup of adipose tissue. We found that genetic blockade of γ-secretase in adipocytes leads to a decrease in EMR1 (F4/80) expression, as a marker of macrophage presence, in adipose tissue without changes in expression of markers of other inflammatory cell types. To explore the mechanism by which adipocytes can alter macrophage function in vitro , fully differentiated 3T3-L1 adipocytes were treated with a γ-secretase inhibitor in the presence of lipopolysaccharide (LPS) and transcription of IL6 and ccl2 (MCP1) were quantified. IL-6 expression and secretion were significantly inhibited by γ-secretase blockade, with little effect on MCP1. Preconditioned media from 3T3-L1 adipocytes treated with a γ-secretase inhibitor also alters macrophage activation but did not affect macrophage translocation in vitro . Therefore, γ-secretase inhibition in fully differentiated adipocytes can alter IL-6 signalling to macrophages, consistent with our hypothesis that that γ-secretase is involved in adipocyte-initiated inflammatory signalling cascades.
- Published
- 2020
- Full Text
- View/download PDF
17. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study.
- Author
-
Gentry CA, Humphrey MB, Thind SK, Hendrickson SC, Kurdgelashvili G, and Williams RJ 2nd
- Abstract
Background: Hydroxychloroquine is one of several agents being evaluated in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We aimed to examine whether patients with rheumatological conditions receiving chronic hydroxychloroquine therapy are at less risk of developing SARS-CoV-2 infection than those not receiving hydroxychloroquine., Methods: This retrospective cohort study included de-identified information of all veterans in the US Veterans Health Administration clinical administrative database aged 18 years or older with rheumatoid arthritis, systemic lupus erythematosus, or associated rheumatological conditions (based on International Classification of Diseases, 10th edition, diagnostic codes) who were alive on March 1, 2020. A propensity score was calculated for each patient, and each patient who was receiving hydroxychloroquine was matched to two patients who were not receiving hydroxychloroquine (controls). The primary endpoint was the proportion of patients with PCR-confirmed SARS-CoV-2 infection among those receiving chronic hydroxychloroquine versus the propensity-matched patients not receiving chronic hydroxychloroquine between March 1 and June 30, 2020. Secondary outcomes were hospital admission associated with SARS-CoV-2 infection; intensive care requirement associated with SARS-CoV-2 infection; mortality associated with SARS-CoV-2 infection; and overall rates of any hospital admission and mortality (ie, all cause). Multivariate logistic regression analysis was done to determine independent variables for the development of active SARS-CoV-2 infection., Findings: Between March 1 and June 30, 2020, 10 703 patients receiving hydroxychloroquine and 21 406 patients not receiving hydroxychloroquine were included in the primary analysis. The incidence of active SARS-CoV-2 infections during the study period did not differ between patients receiving hydroxychloroquine and patients not receiving hydroxychloroquine (31 [0·3%] of 10 703 vs 78 [0·4%] of 21 406; odds ratio 0·79, 95% CI 0·52-1·20, p=0·27). There were no significant differences in secondary outcomes between the two groups in patients who developed active SARS-CoV-2 infection. For all patients in the study, overall mortality was lower in the hydroxychloroquine group than in the group of patients who did not receive hydroxychloroquine (odds ratio 0·70, 95% CI 0·55-0·89, p=0·0031). In multivariate logistic regression analysis, receipt of hydroxychloroquine was not associated with the development of active SARS-CoV-2 infection (odds ratio 0·79, 95% CI 0·51-1·42)., Interpretation: Hydroxychloroquine was not associated with a preventive effect against SARS-CoV-2 infection in a large group of patients with rheumatological conditions., Funding: None., (© 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
18. Control of PTH secretion by the TRPC1 ion channel.
- Author
-
Onopiuk M, Eby B, Nesin V, Ngo P, Lerner M, Gorvin CM, Stokes VJ, Thakker RV, Brandi ML, Chang W, Humphrey MB, Tsiokas L, and Lau K
- Subjects
- Animals, Calcium Signaling physiology, Female, Humans, Hypercalcemia congenital, Hypercalcemia metabolism, Male, Mice, Mice, Knockout, Parathyroid Glands metabolism, Rats, Parathyroid Hormone metabolism, TRPC Cation Channels metabolism
- Abstract
Familial hypocalciuric hypercalcemia (FHH) is a genetic condition associated with hypocalciuria, hypercalcemia, and, in some cases, inappropriately high levels of circulating parathyroid hormone (PTH). FHH is associated with inactivating mutations in the gene encoding the Ca2+-sensing receptor (CaSR), a GPCR, and GNA11 encoding G protein subunit α 11 (Gα11), implicating defective GPCR signaling as the root pathophysiology for FHH. However, the downstream mechanism by which CaSR activation inhibits PTH production/secretion is incompletely understood. Here, we show that mice lacking the transient receptor potential canonical channel 1 (TRPC1) develop chronic hypercalcemia, hypocalciuria, and elevated PTH levels, mimicking human FHH. Ex vivo and in vitro studies revealed that TRPC1 serves a necessary and sufficient mediator to suppress PTH secretion from parathyroid glands (PTGs) downstream of CaSR in response to high extracellular Ca2+ concentration. Gα11 physically interacted with both the N- and C-termini of TRPC1 and enhanced CaSR-induced TRPC1 activity in transfected cells. These data identify TRPC1-mediated Ca2+ signaling as an essential component of the cellular apparatus controlling PTH secretion in the PTG downstream of CaSR.
- Published
- 2020
- Full Text
- View/download PDF
19. TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A Randomized Clinical Trial.
- Author
-
Stavrakis S, Stoner JA, Humphrey MB, Morris L, Filiberti A, Reynolds JC, Elkholey K, Javed I, Twidale N, Riha P, Varahan S, Scherlag BJ, Jackman WM, Dasari TW, and Po SS
- Subjects
- Aged, Atrial Fibrillation physiopathology, Double-Blind Method, Ear, External physiology, Electrocardiography, Female, Humans, Male, Middle Aged, Vagus Nerve physiology, Atrial Fibrillation therapy, Transcutaneous Electric Nerve Stimulation methods
- Abstract
Objectives: This study was a sham-controlled, double-blind, randomized clinical trial to examine the effect of chronic low level tragus stimulation (LLTS) in patients with paroxysmal AF., Background: Low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve at the tragus (LLTS) acutely suppresses atrial fibrillation (AF) in humans, but the chronic effect remains unknown., Methods: LLTS (20 Hz, 1 mA below the discomfort threshold) was delivered using an ear clip attached to the tragus (active arm) (n = 26) or the ear lobe (sham control arm) (n = 27) for 1 h daily over 6 months. AF burden over 2-week periods was assessed by noninvasive continuous electrocardiogram monitoring at baseline, 3 months, and 6 months. Five-minute electrocardiography and serum were obtained at each visit to measure heart rate variability and inflammatory cytokines, respectively., Results: Baseline characteristics were balanced between the 2 groups. Adherence to the stimulation protocol (≤4 sessions lost per month) was 75% in the active arm and 83% in the control arm (p > 0.05). At 6 months, the median AF burden was 85% lower in the active arm compared with the control arm (ratio of medians: 0.15; 95% confidence interval: 0.03 to 0.65; p = 0.011). Tumor necrosis factor-alpha was significantly decreased by 23% in the active group relative to the control group (ratio of medians: 0.77; 95% confidence interval: 0.63 to 0.94; p = 0.0093). Frequency domain indices of heart rate variability were significantly altered with active versus control stimulation (p < 0.01). No device-related side effects were observed., Conclusions: Chronic, intermittent LLTS resulted in lower AF burden than did sham control stimulation, supporting its use to treat paroxysmal AF in selected patients. (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation [TREAT-AF]; NCT02548754)., (Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
20. Glucocorticoid-Induced Osteoporosis. Reply.
- Author
-
Humphrey MB and Buckley L
- Subjects
- Glucocorticoids, Humans, Bone Density Conservation Agents, Osteoporosis
- Published
- 2019
- Full Text
- View/download PDF
21. Low-level transcutaneous vagus nerve stimulation attenuates cardiac remodelling in a rat model of heart failure with preserved ejection fraction.
- Author
-
Zhou L, Filiberti A, Humphrey MB, Fleming CD, Scherlag BJ, Po SS, and Stavrakis S
- Subjects
- Animals, Heart Ventricles physiopathology, Male, Rats, Inbred Dahl, Rats, Sprague-Dawley, Sodium Chloride, Dietary metabolism, Stroke Volume physiology, Vagus Nerve metabolism, Ventricular Function, Left physiology, Heart Failure physiopathology, Hypertension physiopathology, Vagus Nerve physiopathology, Vagus Nerve Stimulation
- Abstract
New Findings: What is the central question of this study? What is the effect of chronic intermittent low-level transcutaneous vagus nerve stimulation on cardiac inflammation, fibrosis and diastolic dysfunction in a rat model of heart failure with preserved ejection fraction? What is the main finding and its importance? In salt-sensitive rats fed with high salt diet, low-level transcutaneous vagus nerve stimulation significantly attenuated blood pressure elevation, ameliorated diastolic function, and attenuated left ventricular inflammation and fibrosis compared to the sham group. Further studies to examine the efficacy of this novel treatment in humans are warranted., Abstract: Inflammation and fibrosis play a central role in the development of heart failure with preserved ejection fraction (HFpEF). We previously showed that low-level, transcutaneous stimulation of the vagus nerve at the tragus (LLTS) is anti-inflammatory. We investigated the effect of chronic intermittent LLTS on cardiac inflammation, fibrosis and diastolic dysfunction in a rat model of HFpEF. Dahl salt-sensitive (DS) rats were randomized in three groups: low salt (LS, 0.3% NaCl; n = 12; control group without stimulation) and high salt (HS, 4% NaCl) with either active (n = 18) or sham (n = 18) LLTS at 7 weeks of age. After 6 weeks of diet (baseline), sham or active LLTS (20 Hz, 2 mA, 0.2 ms) was implemented for 30 min daily for 4 weeks. Echocardiography was performed at baseline and 4 weeks after treatment (endpoint). At endpoint, left ventricle (LV) histology and gene expression were examined. After 6 weeks of diets, HS rats developed hypertension and LV hypertrophy compared to LS rats. At endpoint, LLTS significantly attenuated blood pressure elevation, prevented the deterioration of diastolic function and improved LV circumferential strain, compared to the HS sham group. LV inflammatory cell infiltration and fibrosis were attenuated in the HS active compared to the HS sham group. Pro-inflammatory and pro-fibrotic genes (tumour necrosis factor, osteopontin, interleukin (IL)-11, IL-18 and IL-23A) were differentially altered in the two groups. Chronic intermittent LLTS ameliorates diastolic dysfunction, and attenuates cardiac inflammation and fibrosis in a rat model of HFpEF, suggesting that LLTS may be used clinically as a novel non-invasive neuromodulation therapy in HFpEF., (© 2018 The Authors. Experimental Physiology © 2018 The Physiological Society.)
- Published
- 2019
- Full Text
- View/download PDF
22. Glucocorticoid-Induced Osteoporosis.
- Author
-
Buckley L and Humphrey MB
- Subjects
- Aged, Bone Density, Female, Glucocorticoids therapeutic use, Humans, Osteoporosis prevention & control, Polymyalgia Rheumatica drug therapy, Practice Guidelines as Topic, Prednisone therapeutic use, Risk Assessment, Bone Density Conservation Agents therapeutic use, Diphosphonates therapeutic use, Fractures, Bone prevention & control, Glucocorticoids adverse effects, Osteoporosis chemically induced, Prednisone adverse effects
- Published
- 2018
- Full Text
- View/download PDF
23. TLR4 Promotes and DAP12 Limits Obesity-Induced Osteoarthritis in Aged Female Mice.
- Author
-
Kalaitzoglou E, Lopes EBP, Fu Y, Herron JC, Flaming JM, Donovan EL, Hu Y, Filiberti A, Griffin TM, and Humphrey MB
- Abstract
Aging and female sex are the strongest risk factors for nontraumatic osteoarthritis (OA); whereas obesity is a modifiable risk factor accelerating OA. Prior studies indicate that the innate immune receptor toll-like receptor 4 (TLR4) mediates obesity-induced metabolic inflammation and cartilage catabolism via recognition of damage-associated molecular patterns and is increased with aging in OA joints. TLR4 responses are limited by innate immunoreceptor adapter protein DNAX-activating protein of 12kDA (DAP12). We undertook this study to test the hypothesis that TLR4 promotes, whereas DAP12 limits, obesity-accelerated OA in aged female mice. We fed 13- to 15-month-old female WT, TLR4 KO, and DAP12 KO mice a high-fat diet (HFD) or a control diet for 12 weeks, and changes in body composition, glucose tolerance, serum cytokines, and insulin levels were compared. Knee OA was evaluated by histopathology and μCT. Infrapatellar fat pads (IFPs) were analyzed by histomorphometry and F4/80+ crown-like structures were quantified. IFPs and synovium gene expression were analyzed using a targeted insulin resistance and inflammation array. All HFD-treated mice became obese, but only WT and TLR4 KO mice developed glucose intolerance. HFD induced cartilage catabolism in WT and DAP12 KO female mice, but not in TLR4 KO mice. Gene-expression analysis of IFPs and synovium showed significant differences in insulin signaling, adipokines, and inflammation between genotypes and diets. Unlike young mice, systemic inflammation was not induced by HFD in the older female mice independent of genotype. Our findings support the conclusion that TLR4 promotes and DAP12 limits HFD-induced cartilage catabolism in middle-aged female mice., (© 2018 The Authors published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.)
- Published
- 2018
- Full Text
- View/download PDF
24. Immune Contributions to Osteoarthritis.
- Author
-
Lopes EBP, Filiberti A, Husain SA, and Humphrey MB
- Subjects
- Chemokines immunology, Disease Progression, Humans, Osteoarthritis pathology, Synovial Membrane pathology, Synovitis pathology, Complement Activation immunology, Cytokines immunology, Macrophages immunology, Osteoarthritis immunology, Synovitis immunology, T-Lymphocytes immunology
- Abstract
Purpose of the Review: Mounting evidence supports a role of low-grade inflammation in the pathophysiology of osteoarthritis (OA). We review and discuss the role of synovitis, complement activation, cytokines, and immune cell population in OA., Recent Findings: Using newer imaging modalities, synovitis is found in the majority of knees with OA. Complement activation and pro-inflammatory cytokines play a significant role in the development of cartilage destruction and synovitis. Immune cell infiltration of OA synovial tissue by sub-populations of T cells and activated macrophages correlates with OA disease progression and pain. The innate and acquired immune system plays a key role in the low-grade inflammation found associated with OA. Targets of these pathways my hold promise for future disease-modifying osteoarthritis drugs (DMOADs).
- Published
- 2017
- Full Text
- View/download PDF
25. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
- Author
-
Cai X, Xing J, Long CL, Peng Q, and Humphrey MB
- Subjects
- Adaptor Proteins, Signal Transducing deficiency, Animals, Bone Marrow Cells drug effects, Bone Marrow Cells metabolism, Bone Resorption metabolism, Bone Resorption pathology, Cell Differentiation drug effects, Cell Proliferation drug effects, Macrophage Colony-Stimulating Factor pharmacology, Macrophages drug effects, Macrophages metabolism, Membrane Glycoproteins metabolism, Mice, Mice, Inbred C57BL, Osteoblasts drug effects, Osteoclasts drug effects, Osteoporosis metabolism, Osteoporosis pathology, Phosphorylation drug effects, RANK Ligand metabolism, RAW 264.7 Cells, Receptors, Immunologic metabolism, Signal Transduction drug effects, Adaptor Proteins, Signal Transducing metabolism, Bone Remodeling drug effects, Osteoblasts metabolism, Osteoclasts metabolism, Osteogenesis drug effects
- Abstract
Osteoclastogenesis is essential for bone remodeling and normal skeletal maintenance. Receptor activator of NF-κB ligand (RANKL) promotes osteoclast differentiation and function but requires costimulation of immunoreceptor tyrosine-based activation motif (ITAM)-coupled immunoreceptors. Triggering receptor expressed on myeloid cells-2 (TREM2) coupled to ITAM-adaptor protein DNAX activation protein 12kDA (DAP12) provides costimulation of intracellular calcium signaling during osteoclastogenesis. Previously, we found that downstream of kinase-3 (DOK3) physically associates with DAP12 to inhibit toll-like receptor (TLR)-induced inflammatory signaling in macrophages. However, whether and how DOK3 modulates DAP12-dependent osteoclastogenesis is unknown and the focus of this study. Bone microarchitecture and histology of sex- and age-matched wild-type (WT) and DOK3-deficient (DOK3
-/- ) mice were evaluated. Male and female DOK3-/- mice have significantly reduced trabecular bone mass compared with WT mice with increased TRAP+ osteoclasts in vivo. In vitro, DOK3-/- bone marrow-derived macrophages (BMMs) have increased macrophage colony-stimulating factor (M-CSF)-induced proliferation and increased sensitivity to RANKL-induced osteoclastogenesis. Compared with WT, DOK3-/- osteoclasts are significantly larger with more nuclei and have increased resorptive capacity. Mechanistically, DOK3 limits osteoclastogenesis by inhibiting activation of Syk and ERK in response to RANKL and M-CSF. DOK3 is phosphorylated in a DAP12-dependent manner and associates with Grb2 and Cbl. Compared with DAP12-/- mice with high bone mass, DOK3- and DAP12- doubly deficient mice (DKO) have normalized bone mass, indicating that DOK3 also limits DAP12-independent osteoclastogenesis in vivo. In vitro osteoclasts derived from DKO mice are mononuclear with poor resorptive capacity similar to DAP12-/- osteoclasts. Histomorphometry reveals that DOK3-/- mice also have reduced osteoblast parameters. DOK3-/- osteoblasts have reduced in vitro osteoblastogenesis and increased osteoprotegerin (OPG) to RANKL expression ratio compared with WT osteoblasts. Co-culture of WT and DOK3-/- osteoblasts with pre-osteoclasts reveals a reduced capacity of DOK3-/- osteoblasts to support osteoclastogenesis. These data indicate that DOK3 regulates bone remodeling by negatively regulating M-CSF- and RANKL-mediated osteoclastogenesis and positively regulating osteoblastogenesis. © 2017 American Society for Bone and Mineral Research., (© 2017 American Society for Bone and Mineral Research.)- Published
- 2017
- Full Text
- View/download PDF
26. Skeletal complications of rheumatoid arthritis.
- Author
-
Heinlen L and Humphrey MB
- Subjects
- Ankylosis etiology, Ankylosis prevention & control, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Bone Density Conservation Agents therapeutic use, Bone Diseases prevention & control, Glucocorticoids adverse effects, Humans, Osteoporosis drug therapy, Osteoporosis etiology, Osteoporosis prevention & control, Osteoporotic Fractures etiology, Osteoporotic Fractures prevention & control, Practice Guidelines as Topic, Arthritis, Rheumatoid complications, Bone Diseases etiology
- Abstract
Rheumatoid arthritis (RA) is associated with local and systemic inflammation that induces many changes in the skeletal health. Locally, periarticular bone loss and juxta-articular bone erosions may occur while joint ankylosis, generalized bone loss, osteoporosis, and fractures may develop secondary to inflammation. The aim of this narrative review is to summarize the clinical evidence for abnormal skeletal health in RA, the effects of disease modifying anti-rheumatic drugs (DMARDS) on bone health, and the effects of drugs for the prevention or treatment of osteoporosis in the RA population.
- Published
- 2017
- Full Text
- View/download PDF
27. A functional genomics predictive network model identifies regulators of inflammatory bowel disease.
- Author
-
Peters LA, Perrigoue J, Mortha A, Iuga A, Song WM, Neiman EM, Llewellyn SR, Di Narzo A, Kidd BA, Telesco SE, Zhao Y, Stojmirovic A, Sendecki J, Shameer K, Miotto R, Losic B, Shah H, Lee E, Wang M, Faith JJ, Kasarskis A, Brodmerkel C, Curran M, Das A, Friedman JR, Fukui Y, Humphrey MB, Iritani BM, Sibinga N, Tarrant TK, Argmann C, Hao K, Roussos P, Zhu J, Zhang B, Dobrin R, Mayer LF, and Schadt EE
- Subjects
- Adoptive Transfer, Animals, Causality, Cells, Cultured, Colitis chemically induced, Colitis genetics, Datasets as Topic, Disease Models, Animal, Female, Gene Knockdown Techniques, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Intestinal Mucosa metabolism, Macrophages metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, RNA, Small Interfering genetics, T-Lymphocyte Subsets transplantation, Transcriptome, Gene Regulatory Networks, Genes, Regulator, Genomics methods, Inflammatory Bowel Diseases genetics, Models, Genetic
- Abstract
A major challenge in inflammatory bowel disease (IBD) is the integration of diverse IBD data sets to construct predictive models of IBD. We present a predictive model of the immune component of IBD that informs causal relationships among loci previously linked to IBD through genome-wide association studies (GWAS) using functional and regulatory annotations that relate to the cells, tissues, and pathophysiology of IBD. Our model consists of individual networks constructed using molecular data generated from intestinal samples isolated from three populations of patients with IBD at different stages of disease. We performed key driver analysis to identify genes predicted to modulate network regulatory states associated with IBD, prioritizing and prospectively validating 12 of the top key drivers experimentally. This validated key driver set not only introduces new regulators of processes central to IBD but also provides the integrated circuits of genetic, molecular, and clinical traits that can be directly queried to interrogate and refine the regulatory framework defining IBD.
- Published
- 2017
- Full Text
- View/download PDF
28. Corrigendum to "Utilization of Preventive Measures for Glucocorticoid-Induced Osteoporosis among Veterans with Inflammatory Bowel Disease".
- Author
-
Thanou A, Ali T, Haq O, Kaitha S, Morton J, Stavrakis S, and Humphrey MB
- Abstract
[This corrects the article DOI: 10.1155/2013/862312.].
- Published
- 2017
- Full Text
- View/download PDF
29. Low-Level Vagus Nerve Stimulation Suppresses Post-Operative Atrial Fibrillation and Inflammation: A Randomized Study.
- Author
-
Stavrakis S, Humphrey MB, Scherlag B, Iftikhar O, Parwani P, Abbas M, Filiberti A, Fleming C, Hu Y, Garabelli P, McUnu A, Peyton M, and Po SS
- Subjects
- Adult, Aged, Atrial Fibrillation etiology, Cytokines blood, Female, Humans, Interleukin-6 blood, Male, Middle Aged, Prospective Studies, Thoracic Surgery statistics & numerical data, Tumor Necrosis Factor-alpha blood, Vagus Nerve physiopathology, Atrial Fibrillation therapy, Inflammation metabolism, Postoperative Complications physiopathology, Vagus Nerve Stimulation methods
- Abstract
Objectives: This study sought to examine the efficacy of low-level vagus nerve stimulation (LLVNS) in suppressing post-operative atrial fibrillation (POAF) and inflammatory cytokines in patients undergoing cardiac surgery., Background: POAF often complicates cardiac surgery., Methods: Patients undergoing cardiac surgery were randomized to active or sham LLVNS. In all patients, a bipolar wire was sutured to the vagus nerve pre-ganglionic fibers alongside the lateral aspect of the superior vena cava. High-frequency (20 Hz) stimulation, 50% below the threshold for slowing the heart rate, was delivered for 72 h in the LLVNS group. The development of POAF was monitored continuously during the entire hospital stay by use of telemetry. Blood was collected on arrival in the intensive care unit and at 24 and 72 h for measurement of inflammatory cytokines. Patients were followed up within 1 month after cardiac surgery., Results: A total of 54 patients were randomized to either active LLVNS (n = 26) or sham control (n = 28). The baseline characteristics of the patients were balanced in the 2 groups. POAF occurred in 3 patients (12%) in the LLVNS group and 10 patients (36%) in the control group (hazard ratio: 0.28; 95% confidence interval: 0.10 to 0.85; p = 0.027). None of the patients developed any complications as a result of wire placement. At 72 h, serum tumor necrosis factor-α and interleukin-6 levels were significantly lower in the LLVNS group than in the control group., Conclusions: These data suggest that LLVNS suppresses POAF and attenuates inflammation in patients undergoing cardiac surgery. Further studies are warranted., (Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
30. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
- Author
-
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, and McAlindon T
- Subjects
- Bone Density Conservation Agents therapeutic use, Fractures, Bone prevention & control, Humans, Osteoporosis prevention & control, Rheumatology methods, United States, Vitamin D therapeutic use, Clinical Decision-Making methods, Glucocorticoids adverse effects, Osteoporosis chemically induced, Osteoporosis drug therapy, Practice Guidelines as Topic standards, Rheumatology standards
- Abstract
Objective: To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP)., Methods: We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group consensus process to determine the final recommendations and grade their strength. The guideline addresses initial assessment and reassessment in patients beginning or continuing long-term (≥3 months) glucocorticoid (GC) treatment, as well as the relative benefits and harms of lifestyle modification and of calcium, vitamin D, bisphosphonate, raloxifene, teriparatide, and denosumab treatment in the general adult population receiving long-term GC treatment, as well as in special populations of long-term GC users., Results: Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendations in this guideline are conditional (uncertain balance between benefits and harms). Recommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate-to-high fracture risk, continuing calcium plus vitamin D but switching from an oral bisphosphonate to another antifracture medication in adults in whom oral bisphosphonate treatment is not appropriate, and continuing oral bisphosphonate treatment or switching to another antifracture medication in adults who complete a planned oral bisphosphonate regimen but continue to receive GC treatment. Recommendations for special populations, including children, people with organ transplants, women of childbearing potential, and people receiving very high-dose GC treatment, are also made., Conclusion: This guideline provides direction for clinicians and patients making treatment decisions. Clinicians and patients should use a shared decision-making process that accounts for patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies., (© 2017, American College of Rheumatology.)
- Published
- 2017
- Full Text
- View/download PDF
31. Innate Immune Responses and Osteoarthritis.
- Author
-
Kalaitzoglou E, Griffin TM, and Humphrey MB
- Subjects
- Disease Progression, Humans, Inflammation metabolism, Macrophage Activation immunology, Osteoarthritis metabolism, Risk Factors, Synovitis metabolism, Toll-Like Receptor 4 metabolism, Cytokines metabolism, Immunity, Innate physiology, Inflammation immunology, Osteoarthritis immunology, Synovitis immunology
- Abstract
Purpose of the Review: Osteoarthritis (OA) is a chronic, painful joint disease that affects approximately 40% of adults over 70 year. Age is the strongest predictor of OA, while obesity is considered the primary preventable risk factor for OA. Both conditions are associated with abnormal innate immune inflammatory responses that contribute to OA progression and are the focus of this review., Recent Findings: Recent studies have identified risk factors for OA progression including increased innate immune responses secondary to aging-associated myeloid skewing, obesity-related myeloid activation, and synovial tissue hyperplasia with activated macrophage infiltration. Toll-like receptor (TLR)4-induced catabolic responses also play a significant role in OA. The complex interplay between obesity and aging-associated macrophage activation, pro-inflammatory cytokine production from TLR-driven responses, and adipokines leads to a vicious cycle of synovial hyperplasia, macrophage activation, cartilage catabolism, infrapatellar fat pad fibrosis, and joint destruction.
- Published
- 2017
- Full Text
- View/download PDF
32. Parallel mechanisms suppress cochlear bone remodeling to protect hearing.
- Author
-
Jáuregui EJ, Akil O, Acevedo C, Hall-Glenn F, Tsai BS, Bale HA, Liebenberg E, Humphrey MB, Ritchie RO, Lustig LR, and Alliston T
- Subjects
- Animals, Cochlea anatomy & histology, Mice, Mice, Knockout, X-Ray Microtomography, Bone Remodeling physiology, Cochlea physiology, Hearing physiology, Matrix Metalloproteinase 13 deficiency
- Abstract
Bone remodeling, a combination of bone resorption and formation, requires precise regulation of cellular and molecular signaling to maintain proper bone quality. Whereas osteoblasts deposit and osteoclasts resorb bone matrix, osteocytes both dynamically resorb and replace perilacunar bone matrix. Osteocytes secrete proteases like matrix metalloproteinase-13 (MMP13) to maintain the material quality of bone matrix through perilacunar remodeling (PLR). Deregulated bone remodeling impairs bone quality and can compromise hearing since the auditory transduction mechanism is within bone. Understanding the mechanisms regulating cochlear bone provides unique ways to assess bone quality independent of other aspects that contribute to bone mechanical behavior. Cochlear bone is singular in its regulation of remodeling by expressing high levels of osteoprotegerin. Since cochlear bone expresses a key PLR enzyme, MMP13, we examined whether cochlear bone relies on, or is protected from, osteocyte-mediated PLR to maintain hearing and bone quality using a mouse model lacking MMP13 (MMP13(-/-)). We investigated the canalicular network, collagen organization, lacunar volume via micro-computed tomography, and dynamic histomorphometry. Despite finding defects in these hallmarks of PLR in MMP13(-/-) long bones, cochlear bone revealed no differences in these markers, nor hearing loss as measured by auditory brainstem response (ABR) or distortion product oto-acoustic emissions (DPOAEs), between wild type and MMP13(-/-) mice. Dynamic histomorphometry revealed abundant PLR by tibial osteocytes, but near absence in cochlear bone. Cochlear suppression of PLR corresponds to repression of several key PLR genes in the cochlea relative to long bones. These data suggest that cochlear bone uniquely maintains bone quality and hearing independent of MMP13-mediated osteocytic PLR. Furthermore, the cochlea employs parallel mechanisms to inhibit remodeling by osteoclasts and osteoblasts, and by osteocytes, to protect hearing. Understanding the cellular and molecular mechanisms that confer site-specific control of bone remodeling has the potential to elucidate new pathways that are deregulated in skeletal disease., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
33. A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts.
- Author
-
Humphrey MB and Nakamura MC
- Subjects
- Adaptor Proteins, Signal Transducing metabolism, Animals, Biomarkers, Bone Resorption genetics, Bone Resorption immunology, Humans, Immunomodulation, Protein Binding, Protein Interaction Domains and Motifs, RANK Ligand metabolism, Receptor Activator of Nuclear Factor-kappa B metabolism, Receptors, Fc metabolism, Receptors, Immunologic chemistry, Signal Transduction, Bone Resorption metabolism, Osteoclasts metabolism, Receptors, Immunologic metabolism
- Abstract
Osteoclasts require coordinated co-stimulation by several signaling pathways to initiate and regulate their cellular differentiation. Receptor activator for NF-κB ligand (RANKL or TNFSF11), a tumor necrosis factor (TNF) superfamily member, is the master cytokine required for osteoclastogenesis with essential co-stimulatory signals mediated by immunoreceptor tyrosine-based activation motif (ITAM)-signaling adaptors, DNAX-associated protein 12 kDa size (DAP12) and FcεRI gamma chain (FcRγ). The ITAM-signaling adaptors do not have an extracellular ligand-binding domain and, therefore, must pair with ligand-binding immunoreceptors to interact with their extracellular environment. DAP12 pairs with a number of different immunoreceptors including triggering receptor expressed on myeloid cells 2 (TREM2), myeloid DAP12-associated lectin (MDL-1), and sialic acid-binding immunoglobulin-type lectin 15 (Siglec-15); while FcRγ pairs with a different set of receptors including osteoclast-specific activating receptor (OSCAR), paired immunoglobulin receptor A (PIR-A), and Fc receptors. The ligands for many of these receptors in the bone microenvironment remain unknown. Here, we will review immunoreceptors known to pair with either DAP12 or FcRγ that have been shown to regulate osteoclastogenesis. Co-stimulation and the effects of ITAM-signaling have turned out to be complex, and now include paradoxical findings that ITAM-signaling adaptor-associated receptors can inhibit osteoclastogenesis and immunoreceptor tyrosine-based inhibitory motif (ITIM) receptors can promote osteoclastogenesis. Thus, co-stimulation of osteoclastogenesis continues to reveal additional complexities that are important in the regulatory mechanisms that seek to maintain bone homeostasis.
- Published
- 2016
- Full Text
- View/download PDF
34. Differential effects of IGF-1 deficiency during the life span on structural and biomechanical properties in the tibia of aged mice.
- Author
-
Ashpole NM, Herron JC, Estep PN, Logan S, Hodges EL, Yabluchanskiy A, Humphrey MB, and Sonntag WE
- Subjects
- Animals, Disease Models, Animal, Female, Male, Mice, Mice, Inbred C57BL, Tibia diagnostic imaging, Tibial Fractures diagnosis, Tibial Fractures etiology, X-Ray Microtomography, Aging, Bone Density, Insulin-Like Growth Factor I deficiency, Tibia metabolism, Tibial Fractures metabolism
- Abstract
Advanced aging is associated with the loss of structural and biomechanical properties in bones, which increases the risk for bone fracture. Aging is also associated with reductions in circulating levels of the anabolic signaling hormone, insulin-like growth factor (IGF)-1. While the role of IGF-1 in bone development has been well characterized, the impact of the age-related loss of IGF-1 on bone aging remains controversial. Here, we describe the effects of reducing IGF-1 at multiple time points in the mouse life span--early in postnatal development, early adulthood, or late adulthood on tibia bone aging in both male and female igf (f/f) mice. Bone structure was analyzed at 27 months of age using microCT. We find that age-related reductions in cortical bone fraction, cortical thickness, and tissue mineral density were more pronounced when IGF-1 was reduced early in life and not in late adulthood. Three-point bone bending assays revealed that IGF-1 deficiency early in life resulted in reduced maximum force, maximum bending moment, and bone stiffness in aged males and females. The effects of IGF-1 on bone aging are microenvironment specific, as early-life loss of IGF-1 resulted in decreased cortical bone structure and strength along the diaphysis while significantly increasing trabecular bone fraction and trabecular number at the proximal metaphysis. The increases in trabecular bone were limited to males, as early-life loss of IGF-1 did not alter bone fraction or number in females. Together, our data suggest that the age-related loss of IGF-1 influences tibia bone aging in a sex-specific, microenvironment-specific, and time-dependent manner., Competing Interests: Compliance with ethical standards All procedures were approved by and followed the guidelines of the Institutional Animal Care and Use Committee and veterinarians at University of Oklahoma Health Sciences Center (OUHSC).
- Published
- 2016
- Full Text
- View/download PDF
35. IGF-1 Regulates Vertebral Bone Aging Through Sex-Specific and Time-Dependent Mechanisms.
- Author
-
Ashpole NM, Herron JC, Mitschelen MC, Farley JA, Logan S, Yan H, Ungvari Z, Hodges EL, Csiszar A, Ikeno Y, Humphrey MB, and Sonntag WE
- Subjects
- Aging genetics, Animals, Female, Insulin-Like Growth Factor I genetics, Male, Mice, Mice, Transgenic, Osteoporosis genetics, Osteoporosis metabolism, RANK Ligand biosynthesis, RANK Ligand genetics, Receptor, Insulin genetics, Receptor, Insulin metabolism, Time Factors, Aging metabolism, Bone Density, Insulin-Like Growth Factor I metabolism, Sex Characteristics, Signal Transduction, Spine metabolism
- Abstract
Advanced aging is associated with increased risk of bone fracture, especially within the vertebrae, which exhibit significant reductions in trabecular bone structure. Aging is also associated with a reduction in circulating levels of insulin-like growth factor (IGF-1). Studies have suggested that the reduction in IGF-1 compromises healthspan, whereas others report that loss of IGF-1 is beneficial because it increases healthspan and lifespan. To date, the effect of decreases in circulating IGF-1 on vertebral bone aging has not been thoroughly investigated. Here, we delineate the consequences of a loss of circulating IGF-1 on vertebral bone aging in male and female Igf(f/f) mice. IGF-1 was reduced at multiple specific time points during the mouse lifespan: early in postnatal development (crossing albumin-cyclic recombinase [Cre] mice with Igf(f/f) mice); and in early adulthood and in late adulthood using hepatic-specific viral vectors (AAV8-TBG-Cre). Vertebrae bone structure was analyzed at 27 months of age using micro-computed tomography (μCT) and quantitative bone histomorphometry. Consistent with previous studies, both male and female mice exhibited age-related reductions in vertebral bone structure. In male mice, reduction of circulating IGF-1 induced at any age did not diminish vertebral bone loss. Interestingly, early-life loss of IGF-1 in females resulted in a 67% increase in vertebral bone volume fraction, as well as increased connectivity density and increased trabecular number. The maintenance of bone structure in the early-life IGF-1-deficient females was associated with increased osteoblast surface and an increased ratio of osteoprotegerin/receptor-activator of NF-κB-ligand (RANKL) levels in circulation. Within 3 months of a loss of IGF-1, there was a 2.2-fold increase in insulin receptor expression within the vertebral bones of our female mice, suggesting that local signaling may compensate for the loss of circulating IGF-1. Together, these data suggest the age-related loss of vertebral bone density in females can be reduced by modifying circulating IGF-1 levels early in life., (© 2015 American Society for Bone and Mineral Research.)
- Published
- 2016
- Full Text
- View/download PDF
36. Reply: Vagal Modulation of Atrial Fibrillation.
- Author
-
Stavrakis S, Humphrey MB, and Po SS
- Subjects
- Female, Humans, Male, Atrial Fibrillation therapy, Transcutaneous Electric Nerve Stimulation methods, Vagus Nerve Stimulation methods
- Published
- 2015
- Full Text
- View/download PDF
37. Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation.
- Author
-
Stavrakis S, Humphrey MB, Scherlag BJ, Hu Y, Jackman WM, Nakagawa H, Lockwood D, Lazzara R, and Po SS
- Subjects
- Atrial Fibrillation blood, C-Reactive Protein analysis, Electrocardiography, Female, Humans, Male, Middle Aged, Tumor Necrosis Factor-alpha blood, Atrial Fibrillation therapy, Transcutaneous Electric Nerve Stimulation methods, Vagus Nerve Stimulation methods
- Abstract
Background: Transcutaneous low-level tragus electrical stimulation (LLTS) suppresses atrial fibrillation (AF) in canines., Objectives: This study examined the antiarrhythmic and anti-inflammatory effects of LLTS in humans., Methods: Patients with paroxysmal AF who presented for AF ablation were randomized to either 1 h of LLTS (n = 20) or sham control (n = 20). Attaching a flat metal clip onto the tragus produced LLTS (20 Hz) in the right ear (50% lower than the voltage slowing the sinus rate). Under general anesthesia, AF was induced by burst atrial pacing at baseline and after 1 h of LLTS or sham treatment. Blood samples from the coronary sinus and the femoral vein were collected at those time points and then analyzed for inflammatory cytokines, including tumor necrosis factor alpha and C-reactive protein, using a multiplex immunoassay., Results: There were no differences in baseline characteristics between the 2 groups. Pacing-induced AF duration decreased significantly by 6.3 ± 1.9 min compared with baseline in the LLTS group, but not in the control subjects (p = 0.002 for comparison between groups). AF cycle length increased significantly from baseline by 28.8 ± 6.5 ms in the LLTS group, but not in control subjects (p = 0.0002 for comparison between groups). Systemic (femoral vein) but not coronary sinus tumor necrosis factor (TNF)-alpha and C-reactive protein levels decreased significantly only in the LLTS group., Conclusions: LLTS suppresses AF and decreases inflammatory cytokines in patients with paroxysmal AF. Our results support the emerging paradigm of neuromodulation to treat AF., (Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
38. Genome-wide DNA methylation study identifies significant epigenomic changes in osteoarthritic cartilage.
- Author
-
Jeffries MA, Donica M, Baker LW, Stevenson ME, Annan AC, Humphrey MB, James JA, and Sawalha AH
- Subjects
- Adult, Aged, Aged, 80 and over, Cartilage, Articular pathology, DNA Methylation, Female, Hip Joint pathology, Humans, Male, Middle Aged, Osteoarthritis, Hip metabolism, Osteoarthritis, Hip pathology, Cartilage, Articular metabolism, Hip Joint metabolism, Osteoarthritis, Hip genetics
- Abstract
Objective: To perform a genome-wide DNA methylation study to identify DNA methylation changes in osteoarthritic (OA) cartilage tissue., Methods: The contribution of differentially methylated genes to OA pathogenesis was assessed by bioinformatic analysis, gene expression analysis, and histopathologic severity correlation. Genome-wide DNA methylation profiling of >485,000 methylation sites was performed on eroded and intact cartilage from within the same joint of 24 patients undergoing hip arthroplasty for OA. Genes with differentially methylated CpG sites were analyzed to identify overrepresented gene ontologies, pathways, and upstream regulators. The messenger RNA expression of a subset of differentially methylated genes was analyzed by reverse transcription-polymerase chain reaction. Histopathology was graded by modified Mankin score and correlated with DNA methylation., Results: We identified 550 differentially methylated sites in OA. Most (69%) were hypomethylated and enriched among gene enhancers. We found differential methylation in genes with prior links to OA, including RUNX1, RUNX2, DLX5, FURIN, HTRA1, FGFR2, NFATC1, SNCAIP, and COL11A2. Among these, RUNX1, HTRA1, FGFR2, and COL11A2 were also differentially expressed. Furthermore, we found differential methylation in approximately one-third of known OA susceptibility genes. Among differentially methylated genes, upstream regulator analysis showed enrichment of TGFB1 (P = 4.40 × 10(-5) ) and several microRNAs including miR-128 (P = 4.48 × 10(-13) ), miR-27a (P = 4.15 × 10(-12) ), and miR-9 (P = 9.20 × 10(-10) ). Finally, we identified strong correlations between 20 CpG sites and the histologic Mankin score in OA., Conclusion: Our data implicate epigenetic dysregulation of a host of genes and pathways in OA, including a number of OA susceptibility genes. Furthermore, we identified correlations between CpG methylation and histologic severity in OA., (Copyright © 2014 by the American College of Rheumatology.)
- Published
- 2014
- Full Text
- View/download PDF
39. Medication-induced osteoporosis: screening and treatment strategies.
- Author
-
Panday K, Gona A, and Humphrey MB
- Abstract
Drug-induced osteoporosis is a significant health problem and many physicians are unaware that many commonly prescribed medications contribute to significant bone loss and fractures. In addition to glucocorticoids, proton pump inhibitors, selective serotonin receptor inhibitors, thiazolidinediones, anticonvulsants, medroxyprogesterone acetate, aromatase inhibitors, androgen deprivation therapy, heparin, calcineurin inhibitors, and some chemotherapies have deleterious effects on bone health. Furthermore, many patients are treated with combinations of these medications, possibly compounding the harmful effects of these drugs. Increasing physician awareness of these side effects will allow for monitoring of bone health and therapeutic interventions to prevent or treat drug-induced osteoporosis.
- Published
- 2014
- Full Text
- View/download PDF
40. Editorial: lipid kinases and bone homeostasis: lessons learned from phosphoinositide 3-kinase isoform-specific knockouts.
- Author
-
Xing J and Humphrey MB
- Subjects
- Animals, Humans, Male, Bone Resorption enzymology, Osteoclasts physiology, Phosphatidylinositol 3-Kinases physiology
- Published
- 2014
- Full Text
- View/download PDF
41. A physical interaction between the adaptor proteins DOK3 and DAP12 is required to inhibit lipopolysaccharide signaling in macrophages.
- Author
-
Peng Q, Long CL, Malhotra S, and Humphrey MB
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Animals, Cell Line, Cell Membrane genetics, Extracellular Signal-Regulated MAP Kinases genetics, Extracellular Signal-Regulated MAP Kinases immunology, Inflammation chemically induced, Inflammation genetics, Inflammation immunology, Lipopolysaccharides adverse effects, MAP Kinase Signaling System drug effects, Membrane Glycoproteins genetics, Membrane Glycoproteins immunology, Mice, Mice, Mutant Strains, Phosphorylation drug effects, Phosphorylation immunology, Protein Transport genetics, Protein Transport immunology, Receptors, Immunologic genetics, Receptors, Immunologic immunology, Toll-Like Receptor 4 agonists, Toll-Like Receptor 4 genetics, Toll-Like Receptor 4 immunology, Tumor Necrosis Factor-alpha genetics, Tumor Necrosis Factor-alpha immunology, Adaptor Proteins, Signal Transducing immunology, Cell Membrane immunology, Lipopolysaccharides pharmacology, MAP Kinase Signaling System immunology, Macrophages immunology
- Abstract
DNAX-activating protein of 12 kD (DAP12) is an immunoreceptor tyrosine-based activation motif (ITAM)-containing adaptor protein found in myeloid cells and natural killer cells, and it couples to various receptors that mediate either cellular activation or inhibition. DAP12 inhibits Toll-like receptor (TLR) signaling, such as that of TLR4 in response to its ligand lipopolysaccharide (LPS), as well as cytokine responses by coupling to TREM2 (triggering receptor expressed on myeloid cells 2) at the plasma membrane. Understanding the mechanisms that inhibit inflammatory responses in macrophages is important for the development of therapies to treat inflammatory diseases. We show that inhibition of LPS responses by DAP12 is mediated by the adaptor protein DOK3 (downstream of kinase 3). DOK3 physically associated with the ITAM of DAP12 through its phosphotyrosine-binding domain. In response to LPS, DOK3 was phosphorylated in a DAP12- and Src-dependent manner, which led to translocation of phosphorylated DOK3 to the plasma membrane. DOK3-deficient cells exhibited increased production of proinflammatory cytokines and activation of extracellular signal-regulated kinase (ERK). Compared to wild-type mice, DOK3-deficient mice had increased susceptibility to challenge with a sublethal dose of LPS and produced increased serum concentrations of the inflammatory cytokine tumor necrosis factor-α (TNF-α). Together, these data suggest the mechanism by which DAP12 and TREM2 inhibit LPS signaling in macrophages to prevent inflammation.
- Published
- 2013
- Full Text
- View/download PDF
42. A TRPC1 protein-dependent pathway regulates osteoclast formation and function.
- Author
-
Ong EC, Nesin V, Long CL, Bai CX, Guz JL, Ivanov IP, Abramowitz J, Birnbaumer L, Humphrey MB, and Tsiokas L
- Subjects
- Animals, Base Sequence, Cell Division, Cell Line, Codon, DNA Primers, Humans, Mice, Mice, Knockout, Protein Biosynthesis, RNA, Messenger genetics, TRPC Cation Channels genetics, Osteoclasts cytology, TRPC Cation Channels physiology
- Abstract
Ca(2+) signaling is essential for bone homeostasis and skeletal development. Here, we show that the transient receptor potential canonical 1 (TRPC1) channel and the inhibitor of MyoD family, I-mfa, function antagonistically in the regulation of osteoclastogenesis. I-mfa null mice have an osteopenic phenotype characterized by increased osteoclast numbers and surface, which are normalized in mice lacking both Trpc1 and I-mfa. In vitro differentiation of pre-osteoclasts derived from I-mfa-deficient mice leads to an increased number of mature osteoclasts and higher bone resorption per osteoclast. These parameters return to normal levels in osteoclasts derived from double mutant mice. Consistently, whole cell currents activated in response to the depletion of intracellular Ca(2+) stores are larger in pre-osteoclasts derived from I-mfa knock-out mice compared with currents in wild type mice and normalized in cells derived from double mutant mice, suggesting a cell-autonomous effect of I-mfa on TRPC1 in these cells. A new splice variant of TRPC1 (TRPC1ε) was identified in early pre-osteoclasts. Heterologous expression of TRPC1ε in HEK293 cells revealed that it is unique among all known TRPC1 isoforms in its ability to amplify the activity of the Ca(2+) release-activated Ca(2+) (CRAC) channel, mediating store-operated currents. TRPC1ε physically interacts with Orai1, the pore-forming subunit of the CRAC channel, and I-mfa is recruited to the TRPC1ε-Orai1 complex through TRPC1ε suppressing CRAC channel activity. We propose that the positive and negative modulation of the CRAC channel by TRPC1ε and I-mfa, respectively, fine-tunes the dynamic range of the CRAC channel regulating osteoclastogenesis.
- Published
- 2013
- Full Text
- View/download PDF
43. Utilization of Preventive Measures for Glucocorticoid-Induced Osteoporosis among Veterans with Inflammatory Bowel Disease.
- Author
-
Thanou A, Ali T, Haq O, Kaitha S, Morton J, Stavrakis S, and Humphrey MB
- Abstract
Purpose. We examined current osteoporosis prevention practices in patients with inflammatory bowel disease (IBD) on chronic steroid using the 2003 American Gastroenterological Association guidelines as standard of care. Methods. We identified all IBD patients followed at the Oklahoma City VA Medical Center from January 2003 to December 2010, who had been on daily oral steroids (prednisone ≥5 mg or budesonide ≥6 mg) for ≥3 consecutive months. Associations of calcium and vitamin D (vitD) prescribing and bone mineral density (BMD) testing with patient characteristics were examined by logistic regression. Results. Sixty-three of 384 consecutive patients met inclusion criteria. Among 86 steroid courses, calcium and vitD were concurrently prescribed in 46%, and BMD was tested in 30%. There was no association of demographic and clinical characteristics with calcium/vitD prescribing and BMD testing. By multivariate analysis, steroid initiation after 2006, compared to before 2006, was associated with a significant increase in calcium (OR = 3.17 and P = 0.02) and vitD (OR = 2.96 and P = 0.02) prescribing and BMD testing (OR = 4.63 and P = 0.004). Conclusions. We observed a low, yet increasing, adherence to osteoporosis prevention guidelines in IBD since 2003, which highlights the need for continued physician education to enhance guideline awareness and implementation.
- Published
- 2013
- Full Text
- View/download PDF
44. Comparison of titanium soaked in 5 M NaOH or 5 M KOH solutions.
- Author
-
Kim C, Kendall MR, Miller MA, Long CL, Larson PR, Humphrey MB, Madden AS, and Tas AC
- Subjects
- Animals, Calcium Phosphates chemistry, Cell Adhesion drug effects, Cell Line, Cell Proliferation drug effects, Mice, Microscopy, Electron, Scanning, Nanofibers chemistry, Nanofibers ultrastructure, Nanotubes chemistry, Nanotubes ultrastructure, Solutions chemistry, Spectrometry, X-Ray Emission, Surface Properties, Temperature, Titanium pharmacology, Wettability, X-Ray Diffraction, Hydroxides chemistry, Potassium Compounds chemistry, Sodium Hydroxide chemistry, Titanium chemistry
- Abstract
Commercially pure titanium plates/coupons and pure titanium powders were soaked for 24 h in 5 M NaOH and 5 M KOH solutions, under identical conditions, over the temperature range of 37° to 90 °C. Wettability of the surfaces of alkali-treated cpTi coupons was studied by using contact angle goniometry. cpTi coupons soaked in 5 M NaOH or 5 M KOH solutions were found to have hydrophilic surfaces. Hydrous alkali titanate nanofibers and nanotubes were identified with SEM/EDXS and grazing incidence XRD. Surface areas of Ti powders increased > 50–220 times, depending on the treatment, when soaked in the above solutions. A solution was developed to coat amorphous calcium phosphate, instead of hydroxyapatite, on Ti coupon surfaces. In vitro cell culture tests were performed with osteoblast-like cells on the alkali-treated samples.
- Published
- 2013
- Full Text
- View/download PDF
45. E proteins regulate osteoclast maturation and survival.
- Author
-
Long CL, Berry WL, Zhao Y, Sun XH, and Humphrey MB
- Subjects
- ADP-ribosyl Cyclase 1 biosynthesis, Animals, Apoptosis, Bone Remodeling genetics, Bone Resorption, Bone and Bones anatomy & histology, Female, Mice, NFATC Transcription Factors metabolism, Osteoclasts drug effects, Osteoclasts pathology, RANK Ligand pharmacology, Cell Differentiation drug effects, Osteoclasts physiology, Transcription Factor 3 physiology
- Abstract
Osteoclasts are bone-specific polykaryons derived from myeloid precursors under the stimulation of macrophage colony stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL). E proteins are basic helix-loop-helix (bHLH) transcription factors that modulate lymphoid versus myeloid cell fate decisions. To study the role of E proteins in osteoclasts, myeloid-specific E protein gain-of-function transgenic mice were generated. These mice have high bone mass due to decreased osteoclast numbers and increased osteoclast apoptosis leading to overall reductions in resorptive capacity. The molecular mechanism of decreased osteoclast numbers and resorption is in part a result of elevated expression of CD38, a regulator of intracellular calcium pools with known antiosteoclastogenic properties, which increases sensitivity to apoptosis. In vivo, exogenous RANKL stimulation can overcome this inhibition to drive osteoclastogenesis and bone loss. In vitro-derived ET2 osteoclasts are more spread and more numerous with increases in RANK, triggering receptor expressed on myeloid cells 2 (TREM2), and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) compared to wild type. However, their resorptive capacity does not increase accordingly. Thus, E proteins participate in osteoclast maturation and survival in homeostatic bone remodeling., (Copyright © 2012 American Society for Bone and Mineral Research.)
- Published
- 2012
- Full Text
- View/download PDF
46. Cardiac myxoma induced paraneoplastic syndromes: a review of the literature.
- Author
-
Smith M, Chaudhry MA, Lozano P, and Humphrey MB
- Subjects
- Heart Atria, Heart Neoplasms diagnosis, Heart Neoplasms therapy, Humans, Myxoma diagnosis, Myxoma therapy, Paraneoplastic Syndromes diagnosis, Paraneoplastic Syndromes therapy, Heart Neoplasms complications, Myxoma complications, Paraneoplastic Syndromes etiology
- Abstract
Background: Atrial myxomas are the most common benign tumors of the heart and may present with a wide variety of symptoms. Although 45% of patients present with neurological symptoms, a diverse range of systemic symptoms also occur., Methods: A systemic review of the literature related to the diagnosis, treatment, pathogenesis, and symptoms associated with atrial myxomas was performed., Results: Here we summarize the current state of understanding about myxoma pathogenesis and treatments are described. We review the common and rare local and systemic effects of myxomas. Additionally, we review the paraneoplastic and metastatic potential of myxomas., Conclusions: A better understanding of the diverse disease presentations, paraneoplastic syndromes, and side effects of cytokine abnormalities stemming from myxomas will aid the physician in earlier detection and monitoring of disease recurrence., (Published by Elsevier B.V.)
- Published
- 2012
- Full Text
- View/download PDF
47. CD73-generated adenosine promotes osteoblast differentiation.
- Author
-
Takedachi M, Oohara H, Smith BJ, Iyama M, Kobashi M, Maeda K, Long CL, Humphrey MB, Stoecker BJ, Toyosawa S, Thompson LF, and Murakami S
- Subjects
- 3T3 Cells, 5'-Nucleotidase deficiency, 5'-Nucleotidase genetics, Adenosine A2 Receptor Antagonists pharmacology, Animals, Biomarkers metabolism, Bone Diseases, Metabolic diagnostic imaging, Bone Diseases, Metabolic enzymology, Bone Diseases, Metabolic genetics, Bone Diseases, Metabolic pathology, Femur diagnostic imaging, Femur drug effects, Femur pathology, Genotype, Humans, Integrin-Binding Sialoprotein metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Osteoblasts drug effects, Osteoblasts pathology, Osteocalcin metabolism, Osteogenesis, Phenotype, Receptor, Adenosine A2A metabolism, Receptor, Adenosine A2B metabolism, Signal Transduction, Tibia diagnostic imaging, Tibia drug effects, Tibia pathology, Time Factors, Transfection, X-Ray Microtomography, 5'-Nucleotidase metabolism, Adenosine metabolism, Cell Differentiation drug effects, Femur enzymology, Osteoblasts enzymology, Tibia enzymology
- Abstract
CD731 is a GPI-anchored cell surface protein with ecto-5'-nucleotidase enzyme activity that plays a crucial role in adenosine production. While the roles of adenosine receptors (AR) on osteoblasts and osteoclasts have been unveiled to some extent, the roles of CD73 and CD73-generated adenosine in bone tissue are largely unknown. To address this issue, we first analyzed the bone phenotype of CD73-deficient (cd73(-/-)) mice. The mutant male mice showed osteopenia, with significant decreases of osteoblastic markers. Levels of osteoclastic markers were, however, comparable to those of wild-type mice. A series of in vitro studies revealed that CD73 deficiency resulted in impairment in osteoblast differentiation but not in the number of osteoblast progenitors. In addition, over expression of CD73 on MC3T3-E1 cells resulted in enhanced osteoblastic differentiation. Moreover, MC3T3-E1 cells expressed adenosine A(2A) receptors (A(2A)AR) and A(2B) receptors (A(2B)AR) and expression of these receptors increased with osteoblastic differentiation. Enhanced expression of osteocalcin (OC) and bone sialoprotein (BSP) observed in MC3T3-E1 cells over expressing CD73 were suppressed by treatment with an A(2B)AR antagonist but not with an A(2A) AR antagonist. Collectively, our results indicate that CD73 generated adenosine positively regulates osteoblast differentiation via A(2B)AR signaling., (Copyright © 2011 Wiley Periodicals, Inc.)
- Published
- 2012
- Full Text
- View/download PDF
48. Osteoimmunology: the expanding role of immunoreceptors in osteoclasts and bone remodeling.
- Author
-
Long CL and Humphrey MB
- Abstract
The study of bone and immunology (termed osteoimmunology) has led to the discovery of many important similarities between the two systems including shared niches, mechanisms, cytokines and receptors. The bone marrow provides a niche for hematopoietic cells including those of the lymphoid and myeloid lineage. Osteoclasts, specialized polykarons arising from myeloid precursors, bind to bone and resorb the organic and inorganic components through secretion of acid and proteases. Osteoclasts are differentiated and activated by cytokines that can be produced by immune cells and osteoclast activity can be dysregulated in states of autoimmunity or high inflammation. Similar to B and T cells, osteoclasts require coordinated co-stimulation of signaling pathways provided in the form of receptor-associated immunoreceptor tyrosine-based activation motif adaptor proteins, DAP12 and FcRγ, to drive differentiation and activation. In this review, we will cover the differentiation process of osteoclasts from the earliest precursors shown to have differentiation potential and the signals needed to drive these cells into osteoclast commitment and activation.
- Published
- 2012
- Full Text
- View/download PDF
49. Macrophage metalloelastase (MMP-12) deficiency mitigates retinal inflammation and pathological angiogenesis in ischemic retinopathy.
- Author
-
Li J, Wang JJ, Peng Q, Chen C, Humphrey MB, Heinecke J, and Zhang SX
- Subjects
- Animals, Capillary Permeability genetics, Cell Movement genetics, Disease Models, Animal, Enzyme Activation drug effects, Humans, Macrophages immunology, Macrophages metabolism, Matrix Metalloproteinase 12 genetics, Matrix Metalloproteinase Inhibitors pharmacology, Mice, Mice, Knockout, Neovascularization, Pathologic drug therapy, Retinal Vessels metabolism, Retinal Vessels pathology, Retinitis drug therapy, Vascular Endothelial Growth Factor A genetics, Vascular Endothelial Growth Factor A metabolism, Ischemia, Matrix Metalloproteinase 12 deficiency, Neovascularization, Pathologic genetics, Retina metabolism, Retina pathology, Retinitis genetics, Retinitis pathology
- Abstract
Pathological angiogenesis is a major cause of vision loss in ischemic and inflammatory retinal diseases. Recent evidence implicates macrophage metalloelastase (MMP-12), a macrophage-derived elastinolytic protease in inflammation, tissue remodeling and angiogenesis. However, little is known about the role of MMP-12 in retinal pathophysiology. The present study aims to explore the enzyme's contributions to retinal angiogenesis in oxygen-induced retinopathy (OIR) using MMP-12 knockout (KO) mice. We find that MMP-12 expression was upregulated in OIR, accompanied by elevated macrophage infiltration and increased inflammatory markers. Compared to wildtype mice, MMP-12 KO mice had decreased levels of adhesion molecule and inflammatory cytokines and reduced vascular leakage in OIR. Concomitantly, these mice had markedly reduced macrophage content in the retina with impaired macrophage migratory capacity. Significantly, loss of MMP-12 attenuated retinal capillary dropout in early OIR and mitigated pathological retinal neovascularization (NV). Similar results were observed in the study using MMP408, a pharmacological inhibitor of MMP-12. Intriguingly, in contrast to reducing pathological angiogenesis, lack of MMP-12 accelerated revascularization of avascular retina in OIR. Taken together, we conclude that MMP-12 is a key regulator of macrophage infiltration and inflammation, contributing to retinal vascular dysfunction and pathological angiogenesis.
- Published
- 2012
- Full Text
- View/download PDF
50. DOK3 negatively regulates LPS responses and endotoxin tolerance.
- Author
-
Peng Q, O'Loughlin JL, and Humphrey MB
- Subjects
- Animals, Cell Line, Cytokines biosynthesis, Extracellular Signal-Regulated MAP Kinases metabolism, HEK293 Cells, Humans, Mice, SOS1 Protein metabolism, Signal Transduction, Toll-Like Receptors physiology, Ubiquitination, Adaptation, Physiological drug effects, Adaptor Proteins, Signal Transducing physiology, Endotoxins toxicity, Lipopolysaccharides pharmacology
- Abstract
Innate immune activation via Toll-like receptors (TLRs), although critical for host defense against infection, must be regulated to prevent sustained cell activation that can lead to cell death. Cells repeatedly stimulated with lipopolysaccharide (LPS) develop endotoxin tolerance making the cells hypo-responsive to additional TLR stimulation. We show here that DOK3 is a negative regulator of TLR signaling by limiting LPS-induced ERK activation and cytokine responses in macrophages. LPS induces ubiquitin-mediated degradation of DOK3 leading to SOS1 degradation and inhibition of ERK activation. DOK3 mice are hypersensitive to sublethal doses of LPS and have altered cytokine responses in vivo. During endotoxin tolerance, DOK3 expression remains stable, and it negatively regulates the expression of SHIP1, IRAK-M, SOCS1, and SOS1. As such, DOK3-deficient macrophages are more sensitive to LPS-induced tolerance becoming tolerant at lower levels of LPS than wild type cells. Taken together, the absence of DOK3 increases LPS signaling, contributing to LPS-induced tolerance. Thus, DOK3 plays a role in TLR signaling during both naïve and endotoxin-induced tolerant conditions.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.